| |
| |
|
| Insider
Information: |
Kakkis Emil D |
| Relationship: |
|
| City: |
Novato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
603,534 |
|
|
Indirect Shares
|
2,268,639 |
|
|
| Direct
Value |
$26,259,860 |
|
|
|
Indirect Value
|
$91,741,639 |
|
|
| Total
Shares |
2,872,173 |
|
|
| Total
Value |
$118,001,499 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biomarin Pharmaceutical Inc |
BMRN |
Chief Medical Officer |
2009-03-02 |
39,621 |
2009-03-02 |
4,654 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
|
2024-03-01 |
563,913 |
2024-03-01 |
2,263,985 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2021-03-01 |
4 |
AS |
$141.80 |
$4,254,000 |
I/I |
(30,000) |
2,289,741 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2021-01-04 |
4 |
AS |
$136.90 |
$4,107,000 |
I/I |
(30,000) |
2,329,741 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2020-07-13 |
4 |
AS |
$85.35 |
$3,414,000 |
I/I |
(40,000) |
2,419,741 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2021-05-03 |
4 |
AS |
$107.80 |
$3,234,000 |
I/I |
(30,000) |
2,259,741 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2020-11-02 |
4 |
AS |
$96.82 |
$2,904,600 |
I/I |
(30,000) |
2,359,741 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2020-09-01 |
4 |
AS |
$82.63 |
$2,478,900 |
I/I |
(30,000) |
2,389,741 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2021-03-01 |
4 |
D |
$142.47 |
$2,328,245 |
D/D |
(16,342) |
596,052 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2015-10-30 |
4 |
AS |
$98.63 |
$1,991,407 |
D/D |
(20,000) |
615,640 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2015-11-30 |
4 |
AS |
$96.46 |
$1,965,427 |
D/D |
(20,000) |
595,640 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2015-12-30 |
4 |
AS |
$113.30 |
$1,666,198 |
D/D |
(14,502) |
581,138 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-11-15 |
4 |
AS |
$79.39 |
$1,625,753 |
D/D |
(20,000) |
447,147 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2023-10-19 |
4 |
AS |
$33.52 |
$1,604,033 |
D/D |
(47,853) |
599,743 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2023-12-29 |
4 |
AS |
$47.87 |
$1,436,100 |
D/D |
(30,000) |
569,770 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-04-15 |
4 |
AS |
$69.46 |
$1,406,554 |
D/D |
(20,000) |
537,519 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-08-15 |
4 |
AS |
$67.39 |
$1,352,251 |
D/D |
(20,000) |
487,147 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2024-02-07 |
4 |
AS |
$45.00 |
$1,350,000 |
D/D |
(30,000) |
539,770 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-10-14 |
4 |
AS |
$61.97 |
$1,260,360 |
D/D |
(20,000) |
467,147 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-05-16 |
4 |
AS |
$59.37 |
$1,199,095 |
D/D |
(20,000) |
517,519 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-11-25 |
4 |
S |
$15.98 |
$1,198,740 |
D/D |
(75,000) |
39,621 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2016-07-15 |
4 |
AS |
$50.61 |
$1,016,909 |
D/D |
(20,000) |
507,147 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2024-03-01 |
4 |
D |
$53.69 |
$935,119 |
D/D |
(17,417) |
560,781 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2022-12-30 |
4 |
AS |
$45.57 |
$892,352 |
D/D |
(19,582) |
541,108 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2022-03-01 |
4 |
D |
$67.37 |
$819,354 |
D/D |
(12,162) |
582,185 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2023-03-01 |
4 |
D |
$45.65 |
$736,791 |
D/D |
(16,140) |
599,176 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-03-06 |
4 |
AS |
$37.99 |
$686,870 |
D/D |
(18,000) |
86,164 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
